Related Experiment Video

Updated: Dec 25, 2025

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

15.4K

[Methods for androgen receptor splice variant-7 detection: Advances in studies]

Kun Li1, Guang-Rui Fan1, Chao-Hu Chen1

  • 1Research Institute of Urology / Key Laboratory of Gansu Province for Urinary System Diseases / Gansu Provincial Center of Clinical Medicine for Urinary System Diseases, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, China.

Zhonghua Nan Ke Xue = National Journal of Andrology
|April 2, 2020
PubMed

Insights

Androgen receptor splice variant-7 (AR-V7) shows promise as a biomarker for predicting treatment response in castration-resistant prostate cancer (CRPC). Current detection methods need refinement for widespread clinical use.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Castration-resistant prostate cancer (CRPC) treatment lacks predictive biomarkers.
  • Current CRPC therapies include chemotherapy, endocrine therapy, and radium 233 immunotherapy.
  • Androgen receptor splice variant-7 (AR-V7) is implicated in resistance to specific CRPC therapies.

Purpose of the Study:

  • To review current methods for detecting AR-V7.
  • To explore the clinical utility of AR-V7 as a predictive biomarker in CRPC.
  • To bridge the gap between AR-V7 research and clinical application.

Main Methods:

  • Review of existing literature on AR-V7 detection methods.
  • Analysis of studies correlating AR-V7 expression with treatment response.
  • Discussion of challenges and future directions for AR-V7 clinical implementation.

Main Results:

  • AR-V7 is associated with resistance to abiraterone and enzalutamide.
  • AR-V7 is not linked to resistance to taxane-based chemotherapy.
  • AR-V7 has potential as a biomarker for guiding CRPC treatment selection.

Conclusions:

  • AR-V7 is a promising biomarker for predicting therapeutic effects in CRPC.
  • Standardized and accessible AR-V7 detection methods are crucial for clinical adoption.
  • Further research is needed to translate AR-V7 detection from bench to bedside.
Keywords:
androgen receptor splice variant-7castration-resistant prostate cancerprostate cancer

More Related Videos

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency08:53

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency

Published on: September 15, 2021

3.1K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.2K

Related Concept Videos

RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.1K
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
24.5K
Alternative RNA Splicing02:18

Alternative RNA Splicing

4.6K